Danna nan don nuna banners ɗin ku akan wannan shafin kuma ku biya kawai don nasara

Labaran Waya

Sabbin sakamakon gwaji ga majinyata masu Relapsed/Refractory Large B-cell Lymphoma

Written by edita

AbbVie da Genmab A/S a yau sun ba da sanarwar sakamako mafi girma daga rukunin farko na EPCORE ™ NHL-1 lokaci 1/2 gwajin asibiti da ke kimanta epcoritamab (DuoBody®-CD3xCD20), maganin rigakafin bispecific na subcutaneous na bincike. Ƙungiyar binciken ta haɗa da marasa lafiya na 157 tare da relapsed / refractory big B-cell lymphoma (LBCL) wanda ya karbi aƙalla layi biyu na farko na tsarin farfadowa, ciki har da kashi 38.9 wanda ya karbi maganin rigakafi na chimeric antigen receptor (CAR) T-cell far. Dangane da sakamakon saman, kamfanonin za su shiga hukumomin kula da harkokin duniya.

LBCL wani nau'i ne mai saurin girma na lymphoma ba Hodgkin (NHL) - ciwon daji wanda ke tasowa a cikin tsarin lymphatic - wanda ke rinjayar lymphocytes B-cell, nau'in farin jini. Akwai ƙiyasin sabbin maganganu 150,000 na LBCL kowace shekara a duniya. LBCL ya haɗa da babban ƙwayar lymphoma B-cell (DLBCL), wanda shine mafi yawan nau'in NHL a duk duniya kuma yana lissafin kusan 31 bisa dari na duk lokuta na NHL.1,2,3,4

Mohamed Zaki, MD, Ph.D., mataimakin shugaban kasa da shugaban, ci gaban oncology na duniya, ya ce "Muna nufin yin amfani da ƙwararrun ƙwararrun ciwon daji na AbbVie don haɓaka epcoritamab, tare da Genmab, ga wasu masu cutar kansar jini waɗanda ke da iyakacin zaɓuɓɓukan magani," in ji Mohamed Zaki, MD, Ph.D. Abin

Sakamakon babban layi na wannan rukunin ya nuna ingantaccen ƙimar amsawa gabaɗaya (ORR) na kashi 63.1 ta kwamitin nazari mai zaman kansa (IRC). Tsawon matsakaicin lokacin amsawa (DOR) shine watanni 12. Matsakaicin layukan jiyya na farko a cikin wannan rukunin sun kasance 3.5 (layi na 2 zuwa 11 na jiyya). Mafi yawan abubuwan da suka faru na gaggawa na gaggawa na kowane nau'i (mafi girma ko daidai da kashi 20) sun haɗa da ciwon saki na cytokine (CRS) (kashi 49.7), pyrexia (kashi 23.6), gajiya (22.9 bisa dari), neutropenia (21.7 bisa dari), da gudawa (kashi 20.4). Mafi na kowa Grade 3 ko 4 abubuwan da suka faru na gaggawa (mafi girma ko daidai da kashi 5) sun haɗa da neutropenia (kashi 14.6), anemia (kashi 10.2), ƙididdigar neutrophil ya ragu (6.4 bisa dari), da kuma thrombocytopenia (5.7 bisa dari). Bugu da ƙari, abin lura Grade 3 CRS ya kasance kashi 2.5 cikin ɗari. Za a ƙaddamar da bayanan don gabatarwa a taron likita na gaba.

AbbVie da Genmab ne ke haɓaka Epcoritamab a matsayin wani ɓangare na babban haɗin gwiwar kancology na kamfanoni. Kamfanonin sun jajirce wajen kimanta epcoritamab a matsayin monotherapy, kuma a hade, a cikin layin jiyya don nau'ikan cututtukan cututtukan jini, gami da ci gaba na lokaci 3, lakabin buɗewa, gwajin bazuwar kimanta epcoritamab azaman monotherapy a cikin marasa lafiya tare da sake dawowa / refractory DLBCL. (NCT: 04628494).

"Tare tare da abokin aikinmu, AbbVie, za mu yi aiki tare da hukumomin gudanarwa don ƙayyade matakai na gaba da kuma ci gaba da kimanta epcoritamab a cikin gwaje-gwaje na asibiti daban-daban a matsayin wani zaɓi na magani ga marasa lafiya da cututtuka daban-daban na hematological," in ji Jan van de Winkel, Ph. D., babban jami'in gudanarwa, Genmab. "Muna fatan raba sakamakon binciken a taron likita na gaba."

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...